K E N R E S E A R C H Oman Diabetes Devices Market to Reach USD 80M by 2031 Market Research Report August 24, 2026 www kenresearch com Table of Contents 1. Market Definition and Evidence Snapshot 2. Growth Mechanisms and Market Economics 3. What is expanding the demand base ? 4. Why does technology mix matter more than volume ? 5. Where Market Value Is Moving 6. Largest pool : insulin delivery and replacement consumables 7. Fastest shift : continuous and connected monitoring 8. Competition , Regulation and Entry Barriers 9. What determines competitive advantage ? 10. How does regulation shape market entry ? 11. What is the strongest counter - risk ? 12. Decision Framework and Market Outlook 13. Decision Framework 14. Signals to Monitor 15. Frequently Asked Questions 16. What does the Oman diabetes devices market include ? 17. How large is the Oman diabetes devices market in 2025? 18. What is the market forecast through 2031? 19. Which segments and companies are most important ? 20. What is the main opportunity and the main risk ? 21. Methodology and Sources Oman Diabetes Devices Market to Reach USD 80M by 2031 Oman ʼ s diabetes devices market covers glucose monitoring , insulin - delivery and connected management products used across homecare and clinical settings Ken Research estimates the market at USD 68 million in 2025 and projects it to reach USD 80 million by 2031 , a 2.75% CAGR The Oman Diabetes Devices Market is therefore a modest - growth , recurring - revenue category where replacement consumables and technology mix matter more than headline unit expansion The central commercial shift is from mature finger - stick and injection formats toward continuous glucose monitoring , connected platforms and higher - service care models Demand remains supported by a meaningful diabetes burden , but public procurement pressure and lower premium - device coverage can constrain average selling prices The strongest opportunities are likely to come from suppliers that combine reliable replenishment , clinician education , digital connectivity and affordability , rather than relying on standalone hardware alone through the forecast period in Oman Market Definition and Evidence Snapshot The Oman diabetes devices market includes self - monitoring blood glucose devices , continuous glucose monitoring systems , insulin - delivery devices and connected diabetes - management devices sold into hospitals , specialist clinics , pharmacies and homecare It excludes pharmaceutical insulin itself The market is recurring because strips , sensors , pen needles and infusion supplies require frequent replacement , making adherence and replenishment central to revenue durability Base value : Ken Research estimates USD 68 million in 2025 , up from USD 57 million in 2020 Forecast : Revenue is projected at USD 80 million by 2031 , implying a 2.75% CAGR from the 2025 base Segment structure : Insulin Delivery Devices represent the largest product revenue pool , while technology is the fastest - growing segmentation dimension Official signal : Oman ʼ s 2025 WHO STEPS data book reports raised fasting glucose or diabetes medication use in 13.4% of surveyed adults Implication : The strongest growth is mix - led , favoring recurring sensors , connected monitoring and service - enabled device ecosystems rather than basic hardware penetration alone The broader Oman medical devices market shows how import access , distributors , procurement and lifecycle service shape supplier economics Diabetes devices add a stronger recurring - consumables profile Growth Mechanisms and Market Economics Growth is being driven by a larger monitored patient base , rising sensor use and a shift toward homecare Ken Research models 298,000 active device users in 2025 , while user growth outpaces market - value growth That gap matters : suppliers can expand reach without equivalent revenue gains unless they protect replenishment frequency , premium mix and service attachment What is expanding the demand base? Oman ʼ s disease burden creates durable need , but diagnosis and control gaps determine commercial demand Ken Research cites 55.6% prior diagnosis among people with raised glucose and only 26.0% with fasting blood glucose below 7.0 mmol / L Better screening and treatment intensification can therefore expand device use Why does technology mix matter more than volume? Conventional meters and pen - based delivery are mature and exposed to tender price pressure , so more users do not automatically mean higher revenue per patient Continuous sensors and connected platforms create frequent replacement cycles and data - service opportunities The GCC continuous glucose monitoring market provides regional context for this premiumization pathway Where Market Value Is Moving Value is moving toward categories that combine recurring consumables with stronger clinical feedback Ken Research identifies Insulin Delivery Devices as the largest product revenue pool , while real - time continuous glucose monitoring leads the faster - growing technology dimension Today ʼ s largest pool is therefore not necessarily where incremental value creation will concentrate through 2031 Largest pool: insulin delivery and replacement consumables Pens , needles , syringes , pump consumables and accessories remain important because they are repeatedly purchased Their strength is utilization frequency rather than rapid technology adoption Price - sensitive procurement can limit margins , so suppliers need efficient distribution and stock continuity Fastest shift: continuous and connected monitoring Real - time CGM is the leading growth sub - segment within technology because it supports alerts , remote review and treatment adjustment Ken Research projects CGM revenue share to rise from 10.0% in 2025 to 19.0% by 2031 The Oman OTC continuous glucose monitoring market illustrates the parallel move toward patient - managed monitoring Competition, Regulation and Entry Barriers Competition centers on multinational brands with established consumable portfolios , local regulatory partners and tender access Ken Research identifies Abbott Diabetes Care , Roche Diabetes Care , LifeScan , Medtronic and Ascensia Diabetes Care among major participants , while also profiling Dexcom , Insulet , Ypsomed , ARKRAY and Becton Dickinson Supplier strength depends on channel execution as much as product technology What determines competitive advantage? Installed - base access , clinician familiarity , distributor quality and replenishment reliability matter because consumables are not always interchangeable Connected - device vendors also compete on onboarding , remote review and interoperability The GCC digital diabetes management market shows how software and service can enter device economics How does regulation shape market entry? Oman ʼ s Ministry of Health requires medical - device registration and lists a 60 - working - day completion period for the process The official medical device registration service also sets local establishment , manufacturer and agency requirements Regulatory preparation and a capable local partner are therefore practical entry barriers , not administrative afterthoughts What is the strongest counter-risk? The main downside is that user volume may expand faster than market value Public procurement remains price sensitive , and mature products face compression Premium technologies must prove enough clinical and workflow value to justify higher recurring spend Weak reimbursement or stock interruptions could slow conversion For the complete market sizing , segmentation and competitor framework , review the full Oman Diabetes Devices Market report Decision Framework and Market Outlook The base case is steady expansion through 2031 , with value growth increasingly determined by product mix rather than basic penetration Stronger growth would require faster CGM adoption , broader payer support or better conversion from diagnosis to treatment Weaker growth would follow prolonged price compression , reimbursement constraints or poor continuity in imported consumables and connected - device support Decision Framework Stakeholders should take exactly three actions First , suppliers should prioritize recurring - consumable categories where replenishment economics are defensible Second , distributors should build training , inventory and service capabilities around connected monitoring rather than compete only on price Third , investors should separate user growth from revenue growth and test whether higher adoption improves mix , retention and margin Signals to Monitor Track active device users , CGM revenue share , homecare adoption , tender pricing , registration timelines and movement into continuous or automated management Also watch adjacent therapy - format shifts , including the Oman non - injectable insulin market , because treatment - delivery changes can reshape which devices , accessories and monitoring workflows capture value Companies evaluating entry , portfolio expansion or channel strategy can talk to Ken Research about the Oman opportunity and align market assumptions with a practical go - to - market plan Frequently Asked Questions Executive questions focus on what the market includes , how the forecast should be interpreted , which segments matter and where risk sits The answers below use the same 2025 base , 2031 forecast and segment definitions applied throughout the article so that size , growth and opportunity signals remain internally consistent What does the Oman diabetes devices market include? It includes self - monitoring blood glucose devices , continuous glucose monitoring systems , insulin - delivery devices and connected diabetes - management devices used across hospitals , specialist clinics , pharmacies and homecare The scope covers devices and recurring consumables such as strips , sensors , needles and infusion supplies Pharmaceutical insulin itself is outside the device - market definition used here How large is the Oman diabetes devices market in 2025? Ken Research estimates the market at USD 68 million in 2025 The estimate reflects a recurring - care ecosystem spanning monitoring , insulin - delivery and connected management products Historical market value increased from USD 57 million in 2020 , while active device users reached an estimated 298,000 in 2025 , indicating broader access alongside moderate value growth What is the market forecast through 2031? Ken Research projects the Oman diabetes devices market to reach USD 80 million by 2031 , representing a 2.75% CAGR from the 2025 base The forecast is moderate because conventional meters and injection products are mature , while faster - growing continuous glucose monitoring and connected technologies are still increasing their share of the overall revenue mix Which segments and companies are most important? Insulin Delivery Devices form the largest product revenue pool , while real - time continuous glucose monitoring is the leading growth sub - segment within technology Major participants identified include Abbott Diabetes Care , Roche Diabetes Care , LifeScan , Medtronic and Ascensia Diabetes Care Competitive advantage depends on distribution , clinician access , replenishment continuity and service capability What is the main opportunity and the main risk? The main opportunity is the shift toward recurring sensors , connected monitoring and service - enabled diabetes management as clinicians seek better control and remote visibility The main risk is that user growth outpaces value growth because procurement remains price sensitive Suppliers must therefore convert broader access into stronger mix , retention and replenishment rather than assume volume alone will lift revenue Methodology and Sources Research Basis : Ken Research states that its methodology combines desk research on diabetes prevalence , device registration , glucose - monitoring economics and procurement channels with primary interviews involving endocrinologists , diabetes nurse educators , medical - device distributors and pharmacy category managers Findings were validated across 284 respondents and triangulated against patient , shipment , tender - pricing and replacement - cycle assumptions Sources : Market size , segmentation , competitive coverage and forecasts are based on the Ken Research Oman Diabetes Devices Market report Official context was checked against Oman Ministry of Health and WHO STEPS materials , including national blood - glucose indicators and medical - device registration requirements kenresearch com